Neuren Pharmaceuticals Limited (NEU.AX)
AUD 11.01
(5.97%)
AUD 11.01
(5.97%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 205.17 Million AUD | 1310.81% |
| 2022 | 14.54 Million AUD | 356.04% |
| 2021 | 3.18 Million AUD | 348.52% |
| 2020 | 711 Thousand AUD | 44.81% |
| 2019 | 491 Thousand AUD | -93.78% |
| 2018 | 7.88 Million AUD | 1326.58% |
| 2017 | 553 Thousand AUD | -81.99% |
| 2016 | 3.07 Million AUD | 93.94% |
| 2015 | 1.58 Million AUD | 122.34% |
| 2014 | -7.08 Million AUD | -83.6% |
| 2013 | -3.85 Million AUD | 0.0% |
| 2012 | - AUD | 0.0% |
| 2011 | - AUD | -100.0% |
| 2010 | 4.64 Million AUD | -7.1% |
| 2009 | 5 Million AUD | 119.98% |
| 2008 | 2.27 Million AUD | 140.89% |
| 2007 | 944.16 Thousand AUD | 445.86% |
| 2006 | 172.96 Thousand AUD | -59.74% |
| 2005 | 429.66 Thousand AUD | -69.3% |
| 2004 | 1.39 Million AUD | -50.64% |
| 2003 | 2.83 Million AUD | 33.68% |
| 2002 | 2.12 Million AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 6.43 Million AUD | 0.0% |
| 2023 Q2 | 51.83 Million AUD | 0.0% |
| 2023 FY | 205.17 Million AUD | 1310.81% |
| 2023 Q4 | 153.33 Million AUD | 0.0% |
| 2022 Q4 | 14.54 Million AUD | 0.0% |
| 2022 FY | 14.54 Million AUD | 356.04% |
| 2022 Q2 | -4000.00 AUD | 0.0% |
| 2021 Q2 | -4000.00 AUD | 0.0% |
| 2021 FY | 3.18 Million AUD | 348.52% |
| 2021 Q4 | 3.19 Million AUD | 0.0% |
| 2020 FY | 711 Thousand AUD | 44.81% |
| 2020 Q2 | -3000.00 AUD | 0.0% |
| 2020 Q4 | 714 Thousand AUD | 0.0% |
| 2019 FY | 491 Thousand AUD | -93.78% |
| 2019 Q2 | -3000.00 AUD | 0.0% |
| 2019 Q4 | 494 Thousand AUD | 0.0% |
| 2018 Q4 | 10.53 Million AUD | 0.0% |
| 2018 FY | 7.88 Million AUD | 1326.58% |
| 2018 Q2 | -2.64 Million AUD | 0.0% |
| 2017 Q2 | -2.08 Million AUD | 0.0% |
| 2017 Q4 | -2.42 Million AUD | 0.0% |
| 2017 FY | 553 Thousand AUD | -81.99% |
| 2016 Q2 | -6.51 Million AUD | 0.0% |
| 2016 FY | 3.07 Million AUD | 93.94% |
| 2016 Q4 | -3.66 Million AUD | 0.0% |
| 2015 Q4 | -7.56 Million AUD | 0.0% |
| 2015 FY | 1.58 Million AUD | 122.34% |
| 2015 Q2 | -4.89 Million AUD | 0.0% |
| 2014 Q2 | -2.95 Million AUD | 0.0% |
| 2014 Q4 | -4.13 Million AUD | 0.0% |
| 2014 FY | -7.08 Million AUD | -83.6% |
| 2013 Q4 | -2.71 Million AUD | 0.0% |
| 2013 FY | -3.85 Million AUD | 0.0% |
| 2013 Q3 | - AUD | 100.0% |
| 2013 Q2 | -1.14 Million AUD | 0.0% |
| 2013 Q1 | - AUD | 0.0% |
| 2012 Q2 | - AUD | 0.0% |
| 2012 Q3 | - AUD | 0.0% |
| 2012 FY | - AUD | 0.0% |
| 2012 Q4 | - AUD | 0.0% |
| 2012 Q1 | - AUD | 0.0% |
| 2011 Q3 | - AUD | 0.0% |
| 2011 Q1 | - AUD | 0.0% |
| 2011 Q2 | - AUD | 0.0% |
| 2011 FY | - AUD | -100.0% |
| 2011 Q4 | - AUD | 0.0% |
| 2010 Q3 | 1.16 Million AUD | 0.0% |
| 2010 Q1 | 1.16 Million AUD | 0.0% |
| 2010 Q4 | - AUD | -100.0% |
| 2010 FY | 4.64 Million AUD | -7.1% |
| 2010 Q2 | 1.16 Million AUD | 0.0% |
| 2009 Q2 | 1.25 Million AUD | 0.0% |
| 2009 Q4 | 1.16 Million AUD | -7.1% |
| 2009 Q1 | 1.25 Million AUD | 0.0% |
| 2009 Q3 | 1.25 Million AUD | 0.0% |
| 2009 FY | 5 Million AUD | 119.98% |
| 2008 Q2 | 568.59 Thousand AUD | 0.0% |
| 2008 Q3 | 568.59 Thousand AUD | 0.0% |
| 2008 Q4 | 1.25 Million AUD | 119.98% |
| 2008 FY | 2.27 Million AUD | 140.89% |
| 2008 Q1 | 568.59 Thousand AUD | 0.0% |
| 2007 Q3 | 236.04 Thousand AUD | 0.0% |
| 2007 Q1 | 236.04 Thousand AUD | 0.0% |
| 2007 FY | 944.16 Thousand AUD | 445.86% |
| 2007 Q4 | 568.59 Thousand AUD | 140.89% |
| 2007 Q2 | 236.04 Thousand AUD | 0.0% |
| 2006 Q4 | 236.04 Thousand AUD | 445.87% |
| 2006 Q3 | 43.24 Thousand AUD | 0.0% |
| 2006 FY | 172.96 Thousand AUD | -59.74% |
| 2006 Q1 | 43.24 Thousand AUD | 0.0% |
| 2006 Q2 | 43.24 Thousand AUD | 0.0% |
| 2005 Q1 | 107.41 Thousand AUD | 0.0% |
| 2005 Q2 | 107.41 Thousand AUD | 0.0% |
| 2005 Q3 | 107.41 Thousand AUD | 0.0% |
| 2005 Q4 | 43.24 Thousand AUD | -59.74% |
| 2005 FY | 429.66 Thousand AUD | -69.3% |
| 2004 Q2 | 379.13 Thousand AUD | 0.0% |
| 2004 FY | 1.39 Million AUD | -50.64% |
| 2004 Q4 | 107.41 Thousand AUD | -71.67% |
| 2004 Q1 | 379.13 Thousand AUD | 0.0% |
| 2004 Q3 | 379.13 Thousand AUD | 0.0% |
| 2003 Q1 | 708.94 Thousand AUD | 0.0% |
| 2003 Q3 | 708.94 Thousand AUD | 0.0% |
| 2003 FY | 2.83 Million AUD | 33.68% |
| 2003 Q4 | 379.13 Thousand AUD | -46.52% |
| 2003 Q2 | 708.94 Thousand AUD | 0.0% |
| 2002 FY | 2.12 Million AUD | 0.0% |
| 2002 Q1 | 530.33 Thousand AUD | 0.0% |
| 2002 Q2 | 530.33 Thousand AUD | 0.0% |
| 2002 Q3 | 530.33 Thousand AUD | 0.0% |
| 2002 Q4 | 708.94 Thousand AUD | 33.68% |
| 2001 Q4 | 530.33 Thousand AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AdAlta Limited | 1.5 Million AUD | -13506.47% |
| Acrux Limited | -1.28 Million AUD | 16079.283% |
| Actinogen Medical Limited | 9.93 Million AUD | -1965.891% |
| AnteoTech Limited | 460.39 Thousand AUD | -44464.582% |
| Argenica Therapeutics Limited | 2.59 Million AUD | -7797.574% |
| Arovella Therapeutics Limited | -25.97 Thousand AUD | 789868.659% |
| Anatara Lifesciences Ltd | -748.91 Thousand AUD | 27496.349% |
| Alterity Therapeutics Limited | 3.8 Million AUD | -5292.248% |
| Amplia Therapeutics Limited | 4.01 Million AUD | -5015.599% |
| Avecho Biotechnology Limited | -43.79 Thousand AUD | 468587.27% |
| Bio-Gene Technology Limited | -301.44 Thousand AUD | 68162.591% |
| Biome Australia Limited | 7.66 Million AUD | -2575.138% |
| Biotron Limited | -40.49 Thousand AUD | 506727.488% |
| Botanix Pharmaceuticals Limited | -6.55 Million AUD | 3231.692% |
| BTC Health Limited | 16.36 Thousand AUD | -1254019.804% |
| Chimeric Therapeutics Limited | 7.45 Million AUD | -2652.633% |
| CSL Limited | 15.28 Billion AUD | 98.658% |
| Clarity Pharmaceuticals Ltd | 11.5 Million AUD | -1683.088% |
| Clinuvel Pharmaceuticals Limited | 78.09 Million AUD | -162.717% |
| Cynata Therapeutics Limited | 2.31 Million AUD | -8760.347% |
| Dimerix Limited | 583.47 Thousand AUD | -35063.965% |
| EZZ Life Science Holdings Limited | 50.94 Million AUD | -302.733% |
| Hexima Limited | - AUD | -Infinity% |
| Island Pharmaceuticals Limited | 1.25 Million AUD | -16293.264% |
| Immuron Limited | 3.33 Million AUD | -6048.831% |
| Immutep Limited | 1.44 Million AUD | -14109.67% |
| Imugene Limited | -5.83 Million AUD | 3613.344% |
| Invex Therapeutics Ltd | 1.21 Million AUD | -16824.973% |
| Memphasys Limited | 1606.00 AUD | -12775366.999% |
| Nanollose Limited | -348.95 Thousand AUD | 58897.198% |
| Noxopharm Limited | -534.81 Thousand AUD | 38463.833% |
| NeuroScientific Biopharmaceuticals Limited | -91.33 Thousand AUD | 224734.048% |
| Nyrada Inc. | -5164.07 AUD | 3973206.484% |
| Orthocell Limited | 3.68 Million AUD | -5462.65% |
| PharmAust Limited | -1641.00 AUD | 12503085.984% |
| Patrys Limited | 1.39 Million AUD | -14616.644% |
| Paradigm Biopharmaceuticals Limited | 56.81 Thousand AUD | -361045.533% |
| Proteomics International Laboratories Limited | -1.12 Million AUD | 18367.095% |
| Prescient Therapeutics Limited | 3.71 Million AUD | -5426.775% |
| PYC Therapeutics Limited | 22.05 Million AUD | -830.101% |
| Race Oncology Limited | 1.38 Million AUD | -14661.622% |
| Radiopharm Theranostics Limited | -21.3 Million AUD | 1062.89% |
| Recce Pharmaceuticals Ltd | -366.76 Thousand AUD | 56041.085% |
| Starpharma Holdings Limited | 7.65 Million AUD | -2579.561% |
| Telix Pharmaceuticals Limited | 308.5 Million AUD | 33.493% |
| Tissue Repair Ltd | 150.51 Thousand AUD | -136218.276% |
| Zelira Therapeutics Limited | 10.28 Thousand AUD | -1994979.736% |